Adicet Bio
ACET
51 hedge funds and large institutions have $13.6M invested in Adicet Bio in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 12 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
0.12% less ownership
Funds ownership: 0.44% → 0.32% (-0.12%)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
6% less funds holding
Funds holding: 54 → 51 (-3)
49% less capital invested
Capital invested by funds: $26.8M → $13.6M (-$13.2M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $73K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$641K |
| 2 |
Two Sigma Advisers
New York
|
+$354K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$315K |
| 4 |
Two Sigma Investments
New York
|
+$197K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$145K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.25M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$1.09M |
| 3 |
Morgan Stanley
New York
|
-$862K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$811K |
| 5 |
Millennium Management
New York
|
-$436K |
ACET Hedge Fund Activity: Q1 2020 in Review
51 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q1 2020, worth a combined $13.6M — down 49% from $26.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ACET and 11 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 18 added.
The largest buyer was Acadian Asset Management, adding an estimated $641K. The largest seller was Armistice Capital, exiting entirely with an estimated $5.25M sold.
- 51 institutional investors held Adicet Bio (ACET) as of Q1 2020, down from 54 in Q4 2019.
- Funds reported $13.6M of Adicet Bio stock for Q1 2020, down 49% quarter-over-quarter.
- 11 funds opened new Adicet Bio positions in Q1 2020 and 12 closed out, a net change of -1 holder.
- The largest Adicet Bio buyer in Q1 2020 was Acadian Asset Management, an estimated $641K added.
- The largest Adicet Bio seller in Q1 2020 was Armistice Capital, an estimated $5.25M sold.
Based on aggregated 13F filings for Q1 2020.